Inari Medical, Inc.

Inari Medical, Inc. (NARI) priced its initial public offering on May 26, 2020 at $19.00 per share, above its $17.00–$18.00 range, raising $155.8M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $892.1M. BofA Securities was lead-left underwriter, joined by Morgan Stanley, Wells Fargo and Canaccord Genuity. Latham & Watkins advised the company and A&O Shearman advised the underwriters.

Inari Medical, Inc. is a commercial-stage medical device company treating venous diseases with catheter-based mechanical thrombectomy devices. ClotTriever is FDA-cleared to remove clot in deep vein thrombosis, and FlowTriever is cleared for pulmonary embolism; they have treated over 8,500 patients at about 600 U.S. hospitals.

Status

IPO

Ticker

NARI

Exchange

Nasdaq Global Select

Priced

May 26, 2020

IPO price

$19.00

Price range

$17.00–$18.00

Raised

$155.8M

Market cap at IPO price

$892.1M

First filed

Feb 21, 2020

Underwriters

BofA Securities, Morgan Stanley, Wells Fargo and Canaccord Genuity

Company counsel

Latham & Watkins

Underwriters' counsel

A&O Shearman

Sector

Healthcare

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.